Priority Assets


Our Priority Assets are largely maturing clinical development companies, nearing significant value inflection points.

Viamet represents a financial interest for Malin in VIVJOA™, an FDA-approved medication for the treatment of recurrent vulvovaginal candidiasis (RVVC), an unmet need in women’s health, and in a Phase 3 compound for the treatment of onychomycosis, fungal nail infection.

On 28 April 2022, Mycovia (Viamet’s successor company) announced the approval from the US FDA of VIVJOA™ for the treatment of RVVC in females with a history of RVVC and who are not of reproductive potential.

Mycovia is planning its commercial launch of VIVJOA™ in the second quarter of 2022. The approval of VIVJOA™ will result in the initiation of recurring cash inflows to Malin from milestone payments and royalties.

Mycovia (Viamet) Pipeline

Candidate

Indication

IND-enabling

Phase 1

Phase 2

Phase 3

Approved

VT-1161 (VIVJOA™)

Recurrent vulvovaginal candidiasis

VT-1161

Onychomycosis

VT-1598

Cryptococcal meningitis

Candidate: VT-1161 (VIVJOA™)

Indication: Recurrent vulvovaginal candidiasis

IND-enabling

Phase 1

Phase 2

Phase 3

Approved

Candidate: VT-1161

Indication: Onychomycosis

IND-enabling

Phase 1

Phase 2

Phase 3

Approved

Candidate: VT-1129

Indication: Cryptococcal meningitis

IND-enabling

Phase 1

Phase 2

Phase 3

Approved